Y
Yutaka Shimada
Researcher at University of Toyama
Publications - 445
Citations - 15929
Yutaka Shimada is an academic researcher from University of Toyama. The author has contributed to research in topics: Cancer & Esophageal cancer. The author has an hindex of 58, co-authored 441 publications receiving 14980 citations. Previous affiliations of Yutaka Shimada include Kyoto University & Niigata University.
Papers
More filters
Journal ArticleDOI
Transcriptional factor Prox1 plays an essential role in the antiproliferative action of interferon-γ in esophageal cancer cells.
Masatoshi Akagami,Kenji Kawada,Hajime Kubo,Mayumi Kawada,Meiko Takahashi,Junichi Kaganoi,Shigeru Kato,Atsushi Itami,Yutaka Shimada,Go Watanabe,Yoshiharu Sakai +10 more
TL;DR: Prox1 mediates the antiproliferative effect by IFN-γ in ESCC cells and may be a candidate target for novel therapeutic strategies of ESCCs.
Journal ArticleDOI
Prognostic significance of KLF4 expression in gastric cancer
Isaya Hashimoto,Takuya Nagata,Shinichi Sekine,Makoto Moriyama,Kazuto Shibuya,Shozo Hojo,Koshi Matsui,Isaku Yoshioka,Tomoyuki Okumura,Takashi Hori,Yutaka Shimada,Kazuhiro Tsukada +11 more
TL;DR: Low KLF4 expression was found to be negatively associated with overall survival, and may therefore be a useful prognostic marker in gastric cancer patients.
Journal ArticleDOI
Carbohydrate antigens as a risk factor for hematogenous recurrence of esophageal squamous cell carcinoma patients
TL;DR: Patients with lymph node metastasis, in particular those with distant lymph node carcinoma, the expression of sLeA and sLeX may suggest a higher incidence of hematogenous recurrence in esophageal SCC.
Journal ArticleDOI
Molecular mechanisms involved in interleukin-8 production by normal human oesophageal epithelial cells: BILE ACID-INDUCED IL-8 PRODUCTION IN OESOPHAGEAL EPITHELIAL CELLS
Norimasa Yoshida,Eiko Imamoto,Kazuhiko Uchiyama,Masaaki Kuroda,Yuji Naito,Naofumi Mukaida,Atsushi Kawabe,Yutaka Shimada,Yoshikawa Toshiichi,Takeshi Okanoue +9 more
TL;DR: Increase in interleukin‐8 in the oesophageal mucosa has been associated with the pathogenesis of reflux Oesophagitis.
Journal ArticleDOI
Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
Masashi Kanai,Shigemi Matsumoto,Takahumi Nishimura,Yutaka Shimada,Go Watanabe,Toshiyuki Kitano,Akiko Misawa,Hiroshi Ishiguro,Kiyotsugu Yoshikawa,Kazuhiro Yanagihara,Satoshi Teramukai,Michihide Mitsumori,Tsutomu Chiba,Yoshiharu Sakai,Masanori Fukushima +14 more
TL;DR: Combination therapy of docetaxel with nedaplatin was safe and well tolerated; however, the development of more effective therapy is warranted to improve the prognosis of esophageal cancer.